natgillin/translations-raw huggingface dataset:
Selvom administration af 75 mg clopidogrel dagligt ikke ændrede S-warfarins farmakokinetik eller International Normalised Ratio (INR) hos patienter i langtidsbehandling med warfarin, øgede samtidig administration af clopidogrel og warfarin blødningsrisikoen på grund af uafhængige virkninger på hæmostasen. 
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis.
• heparin eller anden medicin til indsprøjtning til at nedsætte dannelse af blodpropper. 
• heparin or any other injectable medicine used to reduce blood clotting,
En farmakodynamisk interaktion mellem clopidogrel/acetylsalicylsyre og heparin er mulig, hvilket kan medføre øget blødningsrisiko. 
A pharmacodynamic interaction between the combination of clopidogrel/acetylsalicylic acid and heparin is possible, leading to increased risk of bleeding.
Bivirkninger, der enten opstod under monoterapi med henholdsvis clopidogrel eller ASA* eller under kombinationsbehandling med clopidogrel og ASA i de kliniske studier eller blev spontant indberettet, er beskrevet i tabellen nedenfor. 
Adverse reactions that occurred with clopidogrel alone, with ASA alone* or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Hvis du har glemt at tage en dosis Clopidogrel/Acetylsalicylsyre Teva til sædvanlig tid, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid. 
If you forget to take Clopidogrel/Acetylsalicylic acid Teva If you forget to take a dose of Clopidogrel/Acetylsalicylic acid Teva, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time.
Muskuloskeletal blødning (hæmartrose), artrit, artralgi, myalgi 
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
• ømhed i munden (stomatitis) 
• sore mouth (stomatitis)
80 mg omeprazol en gang daglig administreret enten samtidigt med clopidogrel eller med 12 timers mellemrum nedsatte eksponeringen for den aktive metabolit med 45 % (støddosis) og 40 % (vedligeholdelsesdosis). 
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose).
Thienopyridiner kan forårsage lette til svære allergiske reaktioner, såsom udslæt, angioødem eller hæmatologiske krydsreaktioner, såsom trombocytopeni og neutropeni. 
Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia.
I TRITON-TIMI 38 og 3 af kohortestudierne (Collet, Sibbing, Giusti), havde den kombinerede gruppe af patienter med status som enten moderat eller ringe metaboliser en højere hyppighed af kardiovaskulære hændelser (død, myokardieinfarkt og slagtilfælde) eller stenttrombose sammenlignet med personer med udtalt metabolisme. 
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
Tests er tilgængelige til at identificere en patients CYP2C19genotype. 
Tests are available to identify a patient's CYP2C19 genotype.
Da SSRI'er påvirker trombocytaktiveringen og øger risikoen for blødning, skal samtidig administration af SSRI'er og clopidogrel ske med forsigtighed. 
Since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.
Hos patienter med nyligt transitorisk cerebral iskæmi eller apopleksi, og med høj risiko for tilbagevendende iskæmiske tilfælde har kombinationen af clopidogrel og ASA vist at kunne øge risikoen for alvorlig blødning. 
In patients with recent transient ischaemic attack or stroke who are at high risk of recurrent ischaemic events, the combination of ASA and clopidogrel has been shown to increase major bleeding.
Patienterne bør informeres om tegn og symptomer på gastrointestinale bivirkninger og hvilke forholdsregler, de skal tage, hvis de opstår (se pkt. 
Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur (see section 4.8).
Eksperimentelle data tyder på, at ibuprofen kan hæmme effekten af lave doser aspirin på trombocytaggregationen, når de administreres samtidigt. 
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly.
CYP2C19*1-allelen svarer til en fuldt funktionel metabolisme, mens CYP2C19*2- og CYP2C19*3allelerne ikke er funktionelle. 
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to nonfunctional metabolism.
Salicylsyren i kombinationen clopidogrel/acetylsalicylsyre har en plasmahalveringstid på ca. 2 timer. 
Salicylic acid in the combination of clopidogrel/acetylsalicylic acid has a plasma half-life of approximately 2 hours.
• Aktive stoffer: clopidogrel og acetylsalicylsyre. 
• The active substances are clopidogrel and acetylsalicylic acid.
Specielt i en post-hoc analyse af 2.172 patienter, som fik indsat stent (17 % af den totale population i CURE-studiet, StentCURE), viste data, at clopidogrel sammenlignet med placebo medførte en signifikant RRR på 26,2 %, med hensyn til det primære sammensatte endepunkt (CV død, MI, apopleksi) og desuden en signifikant RRR på 23,9 % med hensyn til det andet co-primære endepunkt (CV død, MI, apopleksi eller refraktær iskæmi). 
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Du må IKKE tage Clopidogrel/Acetylsalicylsyre Teva under graviditetens tredje trimester. 
Do NOT take Clopidogrel/Acetylsalicylic acid Teva during third trimester of pregnancy.
Et cross-over studie hos 40 raske studiepersoner, 10 i hver af de fire CYP2C19-metaboliske grupper (ultrahurtig, udtalt, moderat eller ringe), evaluerede farmakokinetisk og trombocythæmmende respons ved anvendelse af 300 mg efterfulgt af 75 mg/dag og 600 mg efterfulgt af 150 mg/dag, hver i alt 5 dage (steady-state). 
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Systemorganklasse Almindelig Ikke almindelig Sjælden Meget sjælden, ikke kendt 
Very rare, not known
Derfor anbefales samtidig anvendelse af NSAID'er inklusive Cox-2 hæmmere ikke (se pkt. 
Consequently, the concomitant use of NSAIDs including Cox-2 inhibitors is not recommended (see section 4.4).
I CURE var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (RR = 43,3 %, CI: 24,3 %; 57,5 %) og GPIIb/IIIa-hæmmere (RRR = 18,2 %, CI: 6,5 %; 
The use of clopidogrel in CURE was associated with a decrease in the need for thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Patienter med mastocytose, hos hvem brug af acetylsalicylsyre kan fremkalde alvorlige overfølsomhedsreaktioner (inklusive kredsløbsshock med ansigtsrødme, hypotension, takykardi og opkastning). 
Patients with pre-existing mastocytosis, in whom the use of acetylsalicylic acid may induce severe hypersensitivity reactions (including circulatory shock with flushing, hypotension, tachycardia and vomiting).
Der er tests tilgængelige til at bestemme en patients CYP2C19-genotype. 
Tests are available to determine a patient's CYP2C19 genotype.
Det blev ikke observeret nogen betydende forskelle i eksponering for den aktive metabolit og gennemsnitlig hæmning af trombocytfunktionen (IPA) mellem ultrahurtige, udtalte eller moderate metabolisers. 
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers.
Pakningsstørrelser på 10, 14, 28, 30, 50, 90 og 100 filmovertrukne tabletter. 
Pack sizes of 10, 14, 28, 30, 50, 90 and 100 film-coated tablets.
• luft i maven eller tarmene 
• excessive gas in stomach or intestines
Hyppigheden af CYP2C19-alleller, der resulterer i moderat eller ringe CYP2C19-metabolisme, varierer afhængigt af race/etnisk tilhørsforhold (se Farmakogenetik). 
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
- Hos patienter med akut koronarsyndrom uden elevation af ST-segmentet (ustabil anginapectoris eller myokardieinfarkt uden forekomst af Q-takker): Den optimale varighed af behandlingen er ikke endeligt fastslået. 
- In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established.
Patienter bør evalueres for tidligere overfølsomhed over for thienopyridiner (såsom clopidogrel, ticlopidin, prasugrel), da der er rapporteret om krydsreaktioner mellem thienopyridiner (se pkt. 
Patients should be evaluated for history of hypersensitivity to another thienopyridine (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
ASA i kombinationen clopidogrel/acetylsalicylsyre hydrolyseres hurtigt i plasma til salicylsyre med en halveringstid på 0,3-0,4 timer for ASA-doser op til 75-100 mg. Salicylsyre bliver primært konjugeret i leveren og danner salicylurinsyre, et phenolisk glukuronid, et acylglukuronid og et antal mindre metabolitter. 
The ASA in the combination of clopidogrel/acetylsalicylic acid is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
• carbamazepin eller oxcarbazepin, medicin til behandling af bestemte typer epilepsi. 
• carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy,
Kombinationen clopidogrel/acetylsalicylsyre påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. 
The combination of clopidogrel/acetylsalicylic acid has no or negligible influence on the ability to drive and use machines.
• hævelse i munden 
• swelling in the mouth
Efter 300 mg/75 mg dosisregimet, blev det trombocythæmmende respons nedsat hos personer med ringe metabolisme med en gennemsnitlig IPA (5 μM ADP) på 24 % (24 timer) og 37 % (dag 5), sammenlignet med IPA på 39 % (24 timer) og 58 % (dag 5) for personer med udtalt metabolisme, og 37 % (24 timer) og 60 % (dag 5) hos personer med moderat metabolisme. 
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
COMMIT-studiet, som var designet med 2x2 faktorer, inkluderede 45.852 patienter, der var til rådighed inden for 24 timer efter indtrådte symptomer, som var mistænkt for at være MI, og hvor ekganomalier (dvs. ST-elevation, ST-depression eller venstresidig grenblok) understøttede dette. 
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
Du har fået ordineret Clopidogrel/Acetylsalicylsyre Teva i stedet for de to indholdsstoffer clopidogrel og acetylsalicylsyre enkeltvist for at forebygge blodpropper, fordi du har haft en alvorlig form for smerter i brystet (ustabil angina pectoris) eller et hjerteanfald (myokardieinfarkt). 
You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unstable angina' or heart attack (myocardial infarction).
I CHARISMA og et kohortestudie (Simon), sås kun en øget hyppighed af hændelser hos personer med ringe metabolisme, i sammenligning med personer med udtalt metabolisme. 
In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.
• fluoxetin, fluvoxamin eller moclobemid, medicin mod depression. 
• fluoxetine, fluvoxamine, or moclobemide, medicines to treat depression,
I nogle enkelte tilfælde er der indberettet blødning i øjne, i hjerne, lunger eller led. 
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
Clopidogrel/Acetylsalicylsyre Teva anvendes efter indledning af behandling med clopidogrel og ASA givet separat. 
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of therapy with clopidogrel and ASA given separately.
• urinsur gigt (en tilstand med smertefuld hævelse af led forårsaget af krystaller af urinsyre) 
• gout (a condition of painful, swollen joints caused by uric acid crystals)
Ud fra din sygdom vil lægen bestemme, hvor lang tid du skal tage Clopidogrel/Acetylsalicylsyre Teva. 
Depending on your condition, your doctor will determine the length of time for which you need to take Clopidogrel/Acetylsalicylic acid Teva.
Hvis du har taget for mange Clopidogrel/Acetylsalicylsyre Teva Kontakt straks din læge eller tag på den nærmeste skadestue på grund af den øgede blødningsrisiko. 
If you take more Clopidogrel/Acetylsalicylic acid Teva than you should Contact your doctor or the nearest hospital emergency department immediately because of the increased risk of bleeding.
Efter absorption bliver ASA i kombination clopidogrel/acetylsalicylsyre hydrolyseret til salicylsyre med peak-plasmakoncentration af salicylsyre inden for 1 time efter dosering, sådan at plasmaniveauet af ASA er så godt som udetekterbart 1,5-3 timer efter dosering. 
Following absorption, the ASA in the combination of clopidogrel/acetylsalicylic acid is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Clopidogrel/Acetylsalicylsyre Teva er indiceret til forebyggelse af aterotrombotiske hændelser hos voksne patienter, der allerede tager både clopidogrel og acetylsalicylsyre (ASA). 
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
• Overfølsomhed over for de aktive stoffer eller over for et eller flere af hjælpestofferne anført i pkt. 
• Hypersensitivity to the active substances or to any of the excipients listed in section 2 or section
10 filmovertrukne tabletter 14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 90 filmovertrukne tabletter 100 filmovertrukne tabletter 
10 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets
CURE-studiet omfattede 12.562 patienter med akut koronarsyndrom uden forhøjelse af ST-segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker), som indfandt sig inden for 24 timer efter starten på den seneste episode med brystsmerter eller symptomer, der svarede til iskæmi. 
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Hvis kombinationen clopidogrel/acetylsalicylsyre seponeres, kan patienterne have gavn af fortsat behandling med et trombocytfunktionshæmmende lægemiddel. 
If the use of the combination of clopidogrel/acetylsalicylic acid is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
Clopidogrels/acetylsalicylsyres sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt. 
The safety and efficacy of clopidogrel/acetylsalicylic acid in children and adolescents under 18 years old have not been established.
Pakningsstørrelse på 30 filmovertrukne tabletter. 
Pack size of 30 film-coated tablets.
Kombinationen clopidogrel/acetylsalicylsyre forlænger blødningstiden og bør anvendes med forsigtighed hos patienter med læsioner, der indebærer øget blødningstendens (specielt gastrointestinalt og intraokulært). 
The combination of clopidogrel/acetylsalicylic acid prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Interaktioner mellem følgende lægemidler og højere (antiinflammatoriske) doser af ASA er også blevet rapporteret: Angiotensin converting enzyme (ACE) hæmmere, acetazolamid, antikonvulsiva (phenytoin og valproatsyre), betablokkere, diuretika og orale antidiabetika. 
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, acetazolamide, anticonvulsants (phenytoin and valproic acid), beta blockers, diuretics, and oral hypoglycemic agents.
Akut leversvigt, leverskader, primært hepatocellulær*, hepatitis, forhøjede leverenzymer*, unormal leverfunktionstest 
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic
De almindeligste bivirkninger, der er set med Clopidogrel/Acetylsalicylsyre Teva, er blødning. 
The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Teva is bleeding.
Nyligt transitorisk cerebral iskæmi eller apopleksi 
Recent transient ischaemic attack or stroke
Clopidogrels aktive metabolit hæmmer selektivt bindingen af adenosindiphosphat (ADP) til dets trombocyt P2Y12-receptor og den efterfølgende ADP-medierede aktivering af glykoprotein (GP)IIb-IIIa-komplekset, hvorved trombocytaggregationen hæmmes. 
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Hvis du bliver gravid, mens du tager Clopidogrel/Acetylsalicylsyre Teva, skal du omgående kontakte din læge, da det frarådes at tage Clopidogrel/Acetylsalicylsyre Teva under graviditet. 
If you become pregnant while taking Clopidogrel/Acetylsalicylic acid Teva, consult your doctor immediately as it is recommended not to take Clopidogrel/Acetylsalicylic acid Teva while you are pregnant.
Bulløs dermatitis (toksisk epidermal nekrolyse, StevensJohnsons syndrom, erythema multiforme), angioødem, lægemiddelinduceret overfølsomhed, medikamentel udslæt med eosinofili og systemiske symptomer (DRESS), erytematøst eller eksfoliativt udslæt, urticaria, eksem, lichen planus 
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug induced hypersentsitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
I CLARITY var der en generel stigning i antallet af blødninger i clopidrogrel plus ASA-gruppen versus ASA-gruppen. 
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the group taking ASA alone.
Hvis nogle af følgende situationer gælder for dig, skal du oplyse det til lægen, før du tager Clopidogrel/Acetylsalicylsyre Teva: 
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel/Acetylsalicylic acid Teva:
• nedsat hørelse 
• hearing loss
• hen imod slutningen af graviditeten udsætte moderen og den nyfødte for: - Mulig forlænget blødningstid, en trombocythæmmende effekt, der kan forekomme selv ved meget lave doser; - Hæmning af uteruskontraktioner resulterende i forsinket eller forlænget fødsel. 
• the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which may occur even
15,0 % af patienterne i clopidogrel plus ASA-gruppen og 21,7 % i gruppen behandlet med ASA alene opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds-reduktion på 36 % til fordel for clopidogrel (95 % CI: 24; 47 %; p < 0,001), der hovedsagligt var relateret til en reduktion af infarkt-relaterede okkluderede arterier. 
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p <0.001), mainly related to a reduction in occluded infarct-related arteries.
• hvis du har haft en blodprop i en åre (arterie) i hjernen (iskæmisk slagtilfælde) inden for de seneste 7 dage. 
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred in the last
Blødning i luftvejene (hæmoptyse, pulmonal blødning), bronkospasmer, interstitiel pneumoni, ikke-kardiogent lungeødem ved kronisk brug eller i forbindelse med en overfølsomhedsreaktion på grund af acetylsalicylsyre*, eosinofil pneumoni. 
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, non-cardiogenic pulmonary edema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
Kombinationen clopidogrel/acetylsalicylsyre bør anvendes med forsigtighed hos patienter med peptisk ulcus, gastroduodenal blødning eller mindre øvre gastrointestinale symptomer i anamnesen, da disse kan være tegn på gastrisk ulceration, der kan føre til gastrisk blødning. 
The combination of clopidogrel/acetylsalicylic acid should be used with caution in patients with a history of peptic ulcer or gastroduodenal haemorrhage or minor upper GI symptoms as this may be due to gastric ulceration which may lead to gastric bleeding.
• akut myokardieinfarkt (MI) med elevation af ST-segmentet hos medicinsk behandlede patienter, der er egnede til trombolytisk behandling. 
• ST segment elevation acute myocardial infarction in medically treated patients eligible for
Pakningsstørrelse på 14, 28 og 30 filmovertrukne tabletter. 
Pack sizes of 14, 28 and 30 film-coated tablets.
Clopidogrel/Acetylsalicylsyre Teva indeholder clopidogrel og acetylsalicylsyre (ASA) og tilhører en gruppe medicin, der kaldes blodfortyndende medicin. 
Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products.
Ved midlertidig seponering af trombocythæmmende behandling bør kombinationen clopidogrel/acetylsalicylsyre seponeres 7 dage før kirurgisk indgreb. 
If patients must temporarily stop antiplatelet therapy, the combination of clopidogrel/acetylsalicylic acid should be discontinued 7 days prior to surgery.